Supporting Clinical Research at the Bedside

Article

In this video Pamela K. Ginex, EdD, RN, OCN, discusses a successful partnership between a clinical librarian and the nursing staff at her institution, a collaboration that benefits staff and, ultimately, patients.

In this video Pamela K. Ginex, EdD, RN, OCN, a nurse scientist at the Memorial Sloan Kettering Cancer Center in New York, discusses a successful partnership between a clinical librarian and the nursing staff at her institution, a collaboration that benefits staff and, ultimately, patients.

Please note: Due to technical difficulties with the audio during the shooting of this video, we’ve provided a transcript of the discussion below.

My name is Pamela Ginex, I’m a nurse scientist at Memorial Sloan Kettering, and this is a poster about a collaboration our nursing department has with our medical librarian at Memorial Sloan Kettering.

We have a wonderful partnership where our medical librarian has dedicated time to work with the department of nursing-she comes to our research meetings, our practice meetings, and some of our other meetings to collaborate with nursing. So the nurses know her, love her, and she knows what questions we’re asking, what issues come up, and we’re also able to reach out to her for specific projects.

If we have an idea for an evidence-based practice project, performance improvement or a research project, our nurses are able to reach out to her and work collaboratively to evaluate the literature and see whether there are any gaps that we can fill, or what we’re able to work on going forward.

It’s a great resource for us, because we have a beautiful medical library, lots of librarians who are great resources, so it’s really nice to have dedicated time for a librarian for nursing. We see the benefit of having that collaboration. She’s integrated with all our department and nurses can reach out to her. She does thousands of literature searches a year for the department of nursing, and it’s a huge resource for us. We wanted to highlight that in our poster because we think this may be a resource that other hospitals have that they may be able to capitalize on.

Clinical nurses are very busy-they’re at the bedside, they’re at the chair side, they’re the ones that have the questions and are able to ask the most relevant questions, but they need resources to then answer those questions. This is sort of the first stop in that journey where they’ve evaluated literature to see what is known and what is not known and where the gaps are. We wanted to highlight that here as we feel this is a great resource for our nurses and hopefully other nurses will be able to take advantage of their medical librarians as well.

 

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content